Skip to content
2000
Volume 33, Issue 6
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background

Gastric Cancer (GC) represents a highly prevalent and aggressive form of malignancy. Recent scholarly endeavors have implicated the RNA binding motif protein 15 (RBM15) gene in the onset and progression of cancer. The present study was designed to delve into the expression profile of in GC, assess its prognostic significance, and explore its potential as a viable therapeutic target.

Methods

In this investigation, we conducted a comprehensive analysis of multiple facets related to the gene in GC samples utilizing publicly accessible databases, including TCGA, GEPIA, TIMER, HPA, Kaplan-Meier Plotter, CPADS, and BEST. Specifically, we examined the mRNA expression levels, clinicopathological characteristics, and survival prognosis, conducted gene function enrichment assessments, analyzed mutation profiles, performed immune cell infiltration evaluations, and assessed drug sensitivity. Notably, all parameters employed in the online databases adhered to their respective default settings.

Results

The expression of mRNA is upregulated in GC and exhibits a correlation with a favorable prognosis, with an of 0.74 (95% = 0.62-0.88, = 0.00054). Specifically, its expression is notably higher in tumor tissues compared to normal tissues. Furthermore, expression is associated with differences in pTNM stage, gender, and racial disparities in survival outcomes. Functionally, is implicated in DNA replication and cell cycle regulation. Mutations within the gene are frequently observed in GC. Additionally, a positive correlation has been identified between expression and immune cell infiltration. Drug sensitivity analyses suggest that may represent potential therapeutic targets for GC treatment, further highlighting its pivotal role in the progression of GC.

Conclusion

mRNA is upregulated in GC and significantly associated with a favorable prognosis. It correlates with clinicopathological features, is enriched in DNA replication processes, and is commonly mutated. Its expression also impacts immune cell infiltration and drug sensitivity, indicating its potential as a prognostic marker and therapeutic target in GC.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673356198250217100226
2025-03-06
2026-02-25

  • From This Site

    /content/journals/cmc/10.2174/0109298673356198250217100226
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LiJ. ZuoZ. LaiS. ZhengZ. LiuB. WeiY. HanT. Differential analysis of RNA methylation regulators in gastric cancer based on TCGA data set and construction of a prognostic model.J. Gastrointest. Oncol.20211241384139710.21037/jgo‑21‑32534532096
     [Google Scholar]
  2. MachlowskaJ. BajJ. SitarzM. MaciejewskiR. SitarzR. Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies.Int. J. Mol. Sci.20202111401210.3390/ijms2111401232512697
     [Google Scholar]
  3. SiddiquiA.Z. AlmhannaK. Beyond chemotherapy, PD-1, and HER-2: Novel targets for gastric and esophageal cancer.Cancers 20211317432210.3390/cancers1317432234503132
     [Google Scholar]
  4. LiuJ. SunG. PanS. QinM. OuyangR. LiZ. HuangJ. The Cancer Genome Atlas (TCGA) based m 6 A methylation-related genes predict prognosis in hepatocellular carcinoma.Bioengineered202011175976810.1080/21655979.2020.178776432631107
     [Google Scholar]
  5. ZhouH. YinK. ZhangY. TianJ. WangS. The RNA m6A writer METTL14 in cancers: Roles, structures, and applications.Biochim. Biophys. Acta Rev. Cancer20211876218860910.1016/j.bbcan.2021.18860934375716
     [Google Scholar]
  6. ZhangY. LiuX. LiuL. LiJ. HuQ. SunR. Expression and prognostic significance of m6A-related genes in lung adenocarcinoma.Med. Sci. Monit.202026e91964410.12659/MSM.91964432086933
     [Google Scholar]
  7. Garcia-DiosD.A. LeviD. ShahV. GillettC. SimpsonM.A. HanbyA. TomlinsonI. SawyerE.J. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.Br. J. Cancer2018118227728410.1038/bjc.2017.45029315289
     [Google Scholar]
  8. ChenZ. LiuC. YeT. ZhangY. ChenY. Resveratrol affects ccRCC cell senescence and macrophage polarization by regulating the stability of CCNB1 by RBM15.Epigenomics2023151889591010.2217/epi‑2023‑015037909116
     [Google Scholar]
  9. ZhangJ. WeiJ. SunR. ShengH. YinK. PanY. JimenezR. ChenS. CuiX. ZouZ. YueZ. EmchM.J. HawseJ.R. WangL. HeH.H. XiaS. HanB. HeC. HuangH. A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling.Mol. Cell2023831526922708.e710.1016/j.molcel.2023.06.02437478845
     [Google Scholar]
  10. JiangX. LiuB. NieZ. DuanL. XiongQ. JinZ. YangC. ChenY. The role of m6A modification in the biological functions and diseases.Signal Transduct. Target. Ther.2021617410.1038/s41392‑020‑00450‑x33611339
     [Google Scholar]
  11. YangF. LiuY. XiaoJ. LiB. ChenY. HuA. ZengJ. LiuZ. LiuH. Circ-CTNNB1 drives aerobic glycolysis and osteosarcoma progression via m6A modification through interacting with RBM15.Cell Prolif.2023561e1334410.1111/cpr.1334436181462
     [Google Scholar]
  12. LiY. GuJ. XuF. ZhuQ. ChenY. GeD. LuC. Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma.Brief. Bioinform.2021224bbaa22510.1093/bib/bbaa22533003204
     [Google Scholar]
  13. ZhaoH. XuY. XieY. ZhangL. GaoM. LiS. WangF. m6A regulators is differently expressed and correlated with immune response of esophageal cancer.Front. Cell Dev. Biol.2021965002310.3389/fcell.2021.65002333748145
     [Google Scholar]
  14. ZhaoZ. MengJ. SuR. ZhangJ. ChenJ. MaX. XiaQ. Epitranscriptomics in liver disease: Basic concepts and therapeutic potential.J. Hepatol.202073366467910.1016/j.jhep.2020.04.00932330603
     [Google Scholar]
  15. YueL. ZhangR. ChenS. DuanG. Risk score prediction model of prognosis in GC patients by age and gender combined with m6A modification genes FTO and RBM15.Front. Cell Dev. Biol.20221071070810.3389/fcell.2022.71070835433701
     [Google Scholar]
  16. DengX. SuR. WengH. HuangH. LiZ. ChenJ. RNA N6-methyladenosine modification in cancers: Current status and perspectives.Cell Res.201828550751710.1038/s41422‑018‑0034‑629686311
     [Google Scholar]
  17. YangL. WuS. MaC. SongS. JinF. NiuY. TongW.M. RNA m6A methylation regulators subclassify luminal subtype in breast cancer.Front. Oncol.20211061119110.3389/fonc.2020.61119133585234
     [Google Scholar]
  18. YuanJ. GuanW. LiX. WangF. LiuH. XuG. RBM15-mediating MDR1 mRNA m6A methylation regulated by the TGF-β signaling pathway in paclitaxel-resistant ovarian cancer.Int. J. Oncol.202363411210.3892/ijo.2023.556037594126
     [Google Scholar]
  19. WangQ. ZhangQ. LiQ. ZhangJ. ZhangJ. Clinicopathological and immunological characterization of RNA m6 A methylation regulators in ovarian cancer.Mol. Genet. Genomic Med.202191e154710.1002/mgg3.154733225598
     [Google Scholar]
  20. WangY. ChenZ. RETRACTED ARTICLE: Long noncoding RNA UBA6-AS1 inhibits the malignancy of ovarian cancer cells via suppressing the decay of UBA6 mRNA.Bioengineered202213117818910.1080/21655979.2021.201164034951345
     [Google Scholar]
  21. ZengX. ChenK. LiL. TianJ. RuanW. HuZ. PengD. ChenZ. Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11.Free Radic. Biol. Med.202218413514710.1016/j.freeradbiomed.2022.03.03135381326
     [Google Scholar]
  22. ZhaoZ. JuQ. JiJ. LiY. ZhaoY. N6-Methyladenosine methylation regulator RBM15 is a potential prognostic biomarker and promotes cell proliferation in pancreatic adenocarcinoma.Front. Mol. Biosci.2022984283310.3389/fmolb.2022.84283335223996
     [Google Scholar]
  23. DongH. ZhangH. MaoX. LiuS. XuW. ZhangY. RBM15 promates the proliferation, migration and invasion of pancreatic cancer cell lines.Cancers2023154108410.3390/cancers1504108436831430
     [Google Scholar]
  24. ZhangC. GuL. XiaoJ. JinF. Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer.BMC Cancer202323168410.1186/s12885‑023‑11163‑z37474926
     [Google Scholar]
  25. NieG. TangB. LvM. LiD. LiT. OuR. XuY. WenJ. HPV E6 promotes cell proliferation of cervical cancer cell by accelerating accumulation of RBM15 dependently of autophagy inhibition.Cell Biol. Int.20234781327134310.1002/cbin.1202037191290
     [Google Scholar]
  26. SongY. WuQ. RBM15 m 6 A modification-mediated OTUB2 upregulation promotes cervical cancer progression via the AKT/mTOR signaling.Environ. Toxicol.20233892155216410.1002/tox.2385237334762
     [Google Scholar]
  27. ZhangZ. MeiY. HouM. Knockdown RBM15 inhibits colorectal cancer cell proliferation and metastasis via N6-methyladenosine (m6A) modification of MyD88 mRNA.Cancer Biother. Radiopharm.2022371097698610.1089/cbr.2021.022634842457
     [Google Scholar]
  28. ChenJ. Regulatory mechanism of RNA binding motif protein 15-mediated N 6 methyladenosine modification in proliferation, invasion, and migration of colorectal cancer cells.Environ. Toxicol.202338112545255910.1002/tox.2388337471637
     [Google Scholar]
  29. JiangT. XingL. ZhaoL. YeZ. YuD. LinS. Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.BMC Med. Genomics202316110510.1186/s12920‑023‑01509‑837194014
     [Google Scholar]
  30. WangX. TianL. LiY. WangJ. YanB. YangL. LiQ. ZhaoR. LiuM. WangP. SunY. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.J. Exp. Clin. Cancer Res.20214018010.1186/s13046‑021‑01871‑433637103
     [Google Scholar]
  31. LinehanW.M. RickettsC.J. The cancer genome atlas of renal cell carcinoma: Findings and clinical implications.Nat. Rev. Urol.201916953955210.1038/s41585‑019‑0211‑531278395
     [Google Scholar]
  32. CharoentongP. FinotelloF. AngelovaM. MayerC. EfremovaM. RiederD. HacklH. TrajanoskiZ. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade.Cell Rep.201718124826210.1016/j.celrep.2016.12.01928052254
     [Google Scholar]
  33. DanaherP. WarrenS. LuR. SamayoaJ. SullivanA. PekkerI. WalldenB. MarincolaF.M. CesanoA. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): Results from the cancer genome atlas (TCGA).J. Immunother. Cancer2018616310.1186/s40425‑018‑0367‑129929551
     [Google Scholar]
  34. HuangL. ChiY. SuX. ZhangH. CaoY. WangX. ZhangS. JiangX. ZhangL. High expression of RAB32 predicts adverse outcomes: A potential therapeutic target for glioblastoma.J. Cancer202415206710672310.7150/jca.9616239668831
     [Google Scholar]
  35. LiuY. LiQ. CaoG. WeiH. XueC. LiuJ. Expression of programmed death receptor-1 ligand (PD-L1) in human cancer is of prognostic value and associated with macrophage infiltration.J. Cancer202415206798680710.7150/jca.9978139668828
     [Google Scholar]
  36. LuJ. YangL. YangX. ChenB. LiuZ. Investigating the clinical significance of OAS family genes in breast cancer: An in vitro and in silico study.Hereditas202416115010.1186/s41065‑024‑00353‑939633486
     [Google Scholar]
  37. KuaiX. WeiC. HeX. WangF. WangC. JiJ. The potential value of RPS27A in Prognosis and Immunotherapy: From pan-cancer analysis to hepatocellular carcinoma validation.ImmunoTargets Ther.20241367369010.2147/ITT.S49321739670220
     [Google Scholar]
  38. TangL. ChenJ. WuZ. WangL. LaiY. ChenZ. PengL. ZhouL. FUNDC1 predicts poor prognosis and promotes progression and chemoresistance in endometrial carcinoma.J. Cancer202415206490650410.7150/jca.9687739668821
     [Google Scholar]
  39. ZhangC. WangY. YuY. PangY. XiaoX. HaoL. Overexpression of ST8Sia1 inhibits tumor progression by TGF-β1 signaling in rectal adenocarcinoma and promotes the tumoricidal effects of CD8+ T cells by granzyme B and perforin.Ann. Med.2025571243953910.1080/07853890.2024.243953939656552
     [Google Scholar]
  40. GaoS. ZhangL. SunG. GLN2 as a key biomarker and therapeutic target: Evidence from a comprehensive pan-cancer study using molecular, functional, and bioinformatic analyses.Discov. Oncol.202415168110.1007/s12672‑024‑01516‑w39562405
     [Google Scholar]
  41. JiK. YuG. ZhouL. ZhangT. LingQ. ManW. ZhuB. ZhangW. [HNRNPA1 gene is highly expressed in colorectal cancer: Its prognostic implications and potential as a therapeutic targetNan Fang Yi Ke Da Xue Xue Bao20244491685169510.12122/j.issn.1673‑4254.2024.09.0839505336
     [Google Scholar]
  42. LvX. GongR. GuoL. WangC. High expression of TBC1 domain family member 22a is related to poor prognosis in ovarian serous cystadenocarcinoma.Int. J. Med. Sci.202421132603261210.7150/ijms.9974439439452
     [Google Scholar]
  43. HouY. ShenH. DongH. Comprehensive analysis of selenoprotein gene expression and prognostic value in ovarian cancer.Turk J. Obstet. Gynecol. 202421424226510.4274/tjod.galenos.2024.6617939663776
     [Google Scholar]
  44. WangD. LvL. DuJ. TianK. ChenY. ChenM. TRIM16 and PRC1 are involved in pancreatic cancer progression and targeted by delphinidin.Chem. Biol. Drug Des.20241046e7002610.1111/cbdd.7002639635962
     [Google Scholar]
  45. ChenC. LiuS. MaY. Comprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment.Heliyon20241022e4032910.1016/j.heliyon.2024.e4032939624281
     [Google Scholar]
  46. LiK. YangH. LinA. XieJ. WangH. ZhouJ. CarrS.R. LiuZ. LiX. ZhangJ. ChengQ. SchrumpD.S. LuoP. WeiT. CPADS: A web tool for comprehensive pancancer analysis of drug sensitivity.Brief. Bioinform.2024253bbae23710.1093/bib/bbae23738770717
     [Google Scholar]
  47. LiuQ. ChenJ. LiuY. ZhangS. FengH. WanT. ZhangS. ZhangN. YangZ. The impact of cathepsins on liver hepatocellular carcinoma: Insights from genetic and functional analyses.Gene202593514906410.1016/j.gene.2024.14906439486661
     [Google Scholar]
  48. WangZ. PanH. ZhouJ. WanD. CBLN2 overexpression inhibits colorectal cancer progression and improves immunotherapy responses.Int. Immunopharmacol.202514411356610.1016/j.intimp.2024.11356639577217
     [Google Scholar]
  49. LiJ. ChenM. TongM. CaoQ. TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma.Front. Immunol.202415145769110.3389/fimmu.2024.145769139301023
     [Google Scholar]
  50. ChenY. MengZ. XiangZ. HMGB2 drives tumor progression and shapes the immunosuppressive microenvironment in hepatocellular carcinoma: Insights from multi-omics analysis.Front. Immunol.202415141543510.3389/fimmu.2024.141543539247201
     [Google Scholar]
  51. WenB. ZhangP. XieJ. ZhouZ. ZhangG. ZhangL. ZhangZ. Deciphering the prognostic role of endoplasmic reticulum stress in lung adenocarcinoma: Integrating prognostic prediction and immunotherapy strategies.Clin. Exp. Med.202424116910.1007/s10238‑024‑01439‑439052154
     [Google Scholar]
  52. ZhouT. CaiZ. MaN. XieW. GaoC. HuangM. BaiY. NiY. TangY. A novel ten-gene signature predicting prognosis in hepatocellular carcinoma.Front. Cell Dev. Biol.2020862910.3389/fcell.2020.0062932760725
     [Google Scholar]
  53. ZhangZ. LinE. ZhuangH. XieL. FengX. LiuJ. YuY. Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma.Cancer Cell Int.20202012710.1186/s12935‑020‑1113‑632002016
     [Google Scholar]
  54. LinW. WuS. ChenX. YeY. WengY. PanY. ChenZ. ChenL. QiuX. QiuS. Characterization of hypoxia signature to evaluate the tumor immune microenvironment and predict prognosis in glioma groups.Front. Oncol.20201079610.3389/fonc.2020.0079632500034
     [Google Scholar]
  55. MayakondaA. LinD.C. AssenovY. PlassC. KoefflerH.P. Maftools: Efficient and comprehensive analysis of somatic variants in cancer.Genome Res.201828111747175610.1101/gr.239244.11830341162
     [Google Scholar]
  56. BiF. ChenY. YangQ. Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer.Cancer Cell Int.202020137310.1186/s12935‑020‑01472‑932774167
     [Google Scholar]
  57. JinK. QiuS. JinD. ZhouX. ZhengX. LiJ. LiaoX. YangL. WeiQ. Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: Bioinformatics analysis of TCGA database.Aging (Albany NY)20211321859187110.18632/aging.10378733465047
     [Google Scholar]
  58. SturmG. FinotelloF. PetitprezF. ZhangJ.D. BaumbachJ. FridmanW.H. ListM. AneichykT. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology.Bioinformatics20193514i436i44510.1093/bioinformatics/btz36331510660
     [Google Scholar]
  59. YangL. ChenY.X. LiY.Y. LiuX.J. JiangY.M. MaiJ. Systematic analysis of expression profiles and prognostic significance for MMDS-related iron–sulfur proteins in renal clear cell carcinoma.Sci. Rep.20221211963710.1038/s41598‑022‑22479‑436385109
     [Google Scholar]
  60. SuY. HuangJ. HuJ. m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gastric cancer.Front. Oncol.20199103810.3389/fonc.2019.0103831681576
     [Google Scholar]
  61. ZhangJ. PiaoH. WangY. MengX. YangD. ZhaoY. ZhengZ. To develop and validate the combination of RNA methylation regulators for the prognosis of patients with gastric cancer.OncoTargets Ther.202013107851079510.2147/OTT.S27623933122917
     [Google Scholar]
  62. JingJ.J. ZhaoX. LiH. SunL. YuanY. Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer.Future Oncol.202117202605262010.2217/fon‑2020‑063033878934
     [Google Scholar]
  63. WangT. KongS. TaoM. JuS. The potential role of RNA N6-methyladenosine in cancer progression.Mol. Cancer20201918810.1186/s12943‑020‑01204‑732398132
     [Google Scholar]
  64. WangX. XuK. LiaoX. RaoJ. HuangK. GaoJ. XuG. WangD. Construction of a survival nomogram for gastric cancer based on the cancer genome atlas of m6A-related genes.Front. Genet.20221393665810.3389/fgene.2022.93665835991573
     [Google Scholar]
  65. JiangA. ZhangS. WangX. LiD. RBM15 condensates modulate m6A modification of STYK1 to promote tumorigenesis.Comput. Struct. Biotechnol. J.2022204825483610.1016/j.csbj.2022.08.06836147665
     [Google Scholar]
  66. MaM. WangW. WangB. YangY. HuangY. ZhaoG. YeL. The prognostic value of N6-methyladenosine RBM15 regulators in lung adenocarcinoma.Cell. Mol. Biol.202268113013910.14715/cmb/2022.68.1.1735809319
     [Google Scholar]
  67. DouX. XiaoY. ShenC. WangK. WuT. LiuC. LiY. YuX. LiuJ. DaiQ. PajdzikK. YeC. GeR. GaoB. YuJ. SunS. ChenM. ChenJ. HeC. RBFOX2 recognizes N6-methyladenosine to suppress transcription and block myeloid leukaemia differentiation.Nat. Cell Biol.20232591359136810.1038/s41556‑023‑01213‑w37640841
     [Google Scholar]
  68. DengX. SunX. HuZ. WuY. ZhouC. SunJ. GaoX. HuangY. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.FASEB J.2023379e2315510.1096/fj.20230134337606566
     [Google Scholar]
  69. JiangJ. QuH. ZhanX. LiuD. LiangT. ChenL. HuangS. SunX. ChenJ. ChenT. LiH. YaoY. LiuC. Identification of osteosarcoma m6A-related prognostic biomarkers using artificial intelligence: RBM15.Sci. Rep.2023131525510.1038/s41598‑023‑28739‑137002245
     [Google Scholar]
  70. FengJ. LiY. HeF. ZhangF. RBM15 silencing promotes ferroptosis by regulating the TGF -β/Smad 2 pathway in lung cancer.Environ. Toxicol.202338495096110.1002/tox.2374136715115
     [Google Scholar]
  71. TianL. WangY. TianJ. SongW. LiL. CheG. Prognostic value and genome signature of m6A/m5C regulated genes in early-stage lung adenocarcinoma.Int. J. Mol. Sci.2023247652010.3390/ijms2407652037047493
     [Google Scholar]
  72. ThandarM. ZhuY. ZhangX. ChenZ. ZhaoY. HuangS. ChiP. Construction and validation of stemness-related lncRNA pair signature for predicting prognosis in colorectal cancer.J. Cancer Res. Clin. Oncol.202314913118151182810.1007/s00432‑023‑05047‑937410143
     [Google Scholar]
  73. SoerjomataramI. CabasagC. BardotA. Fidler-BenaoudiaM.M. Miranda-FilhoA. FerlayJ. ParkinD.M. RanganathanR. PiñerosM. ZnaorA. MeryL. Joko-FruY.W. DikshitR. SankaranarayananR. SwaminathanR. BrayF. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): A population-based benchmarking study in 32 countries.Lancet Oncol.2023241223210.1016/S1470‑2045(22)00704‑536603919
     [Google Scholar]
  74. PatelR. ZhangL. DesaiA. HoenerhoffM.J. KennedyL.H. RadivoyevitchT. BanY. ChenX.S. GersonS.L. WelfordS.M. Mlh1 deficiency increases the risk of hematopoietic malignancy after simulated space radiation exposure.Leukemia20193351135114710.1038/s41375‑018‑0269‑830275527
     [Google Scholar]
  75. LesterD.K. BurtonC. GardnerA. InnamaratoP. KodumudiK. LiuQ. AdhikariE. MingQ. WilliamsonD.B. FrederickD.T. SharovaT. WhiteM.G. MarkowitzJ. CaoB. NguyenJ. JohnsonJ. BeattyM. Mockabee-MaciasA. MercurioM. WatsonG. ChenP.L. McCarthyS. MoranSeguraC. MessinaJ. ThomasK.L. DarvilleL. IzumiV. KoomenJ.M. Pilon-ThomasS.A. RuffellB. LucaV.C. HaltiwangerR.S. WangX. WargoJ.A. BolandG.M. LauE.K. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy.Nat. Can.20234222223910.1038/s43018‑022‑00506‑736690875
     [Google Scholar]
  76. Devi-MarulkarP. FastenackelsS. KarapentiantzP. GocJ. GermainC. KaplonH. KnockaertS. OliveD. PanouillotM. ValidireP. DamotteD. AlifanoM. MurrisJ. KatsahianS. LawandM. Dieu-NosjeanM.C. Regulatory T cells infiltrate the tumor-induced tertiary lymphoïd structures and are associated with poor clinical outcome in NSCLC.Commun. Biol.202251141610.1038/s42003‑022‑04356‑y36566320
     [Google Scholar]
  77. HofmanP. New insights into the interaction of the immune system with non-small cell lung carcinomas.Transl. Lung Cancer Res.2020952199221310.21037/tlcr‑20‑17833209644
     [Google Scholar]
  78. StoltzfusC.R. SivakumarR. KunzL. Olin PopeB.E. MeniettiE. SpezialeD. AdelfioR. BacacM. ColombettiS. PerroM. GernerM.Y. Multi-parameter quantitative imaging of tumor microenvironments reveals perivascular immune niches associated with anti-tumor immunity.Front. Immunol.20211272649210.3389/fimmu.2021.72649234421928
     [Google Scholar]
  79. WuH. WeidingerC. SchmidtF. KeyeJ. FriedrichM. YerindeC. WillimskyG. QinZ. SiegmundB. GlaubenR. Oleate but not stearate induces the regulatory phenotype of myeloid suppressor cells.Sci. Rep.201771749810.1038/s41598‑017‑07685‑928790345
     [Google Scholar]
  80. PylaevaE. KorschunowG. SpyraI. BordbariS. SiakaevaE. OzelI. DomnichM. SquireA. HasenbergA. ThangaveluK. HussainT. GoetzM. LangK.S. GunzerM. HansenW. BuerJ. BankfalviA. LangS. JablonskaJ. During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes.Cell Rep.202240711117110.1016/j.celrep.2022.11117135977505
     [Google Scholar]
  81. ZhuangZ. ChenL. MaoY. ZhengQ. LiH. HuangY. HuZ. JinY. Diagnostic, progressive and prognostic performance of m6 A methylation RNA regulators in lung adenocarcinoma.Int. J. Biol. Sci.202016111785179710.7150/ijbs.3904632398949
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673356198250217100226
Loading
Clinical Significance of RBM15 in Gastric Cancer: A Multi-Database Validation
Curr. Med. Chem. 33, 1212 (2026); https://doi.org/10.2174/0109298673356198250217100226
/content/journals/cmc/10.2174/0109298673356198250217100226
/content/journals/cmc/10.2174/0109298673356198250217100226
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): biomarker; gastric cancer; N6-methyladenosine (m6A); prognosis; prognostic marker; RNA binding motif protein 15

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test